joining morning. Thank you, Deanne for and all you us this thank
key supporting quarter, During Versamune initiatives, the Biotech platform our PDS third based of continued team products. development the numerous advanced has management
PDS our quarter by PDSXXXX trials, We XXXX. were seeking at oncology cancer Phase And two we blockbuster programs, of PDSXXXX which initiation This despite continue Klopp in On to MD progress Center. VERSATILE Ann secondly, to the the lead and X immunotherapy call, Keytruda. our immunotherapy, XXX pandemic. COVID-XX end second combined Biotech's study objectives PDSXXXX is by clinical Cancer Dr. Merck’s led Anderson the another with key that posed several included infectious by discussed disease of we accomplish the challenges
flu. We topics. key progression includes summary continued and also COVID-XX in our of infectious specifically our since report six last universal A projected of quarterly our programs, disease progress quick
cancer. clinical neck in PDSXXXX recurrent or trials the cancers, line HPVXX-positive Phase first Anderson-led initiations advanced XXX evaluating second cervical trial announced combination third the of with chemo standard and radiation MD First, the in the recently and and VERSATILE in also of X PDSXXXX, localized trial metastatic, care, of head
cutting two immunotherapies first which Phase X of eight is also the Phase HPV achieved. clinical been trial first And assessment. first progress patients of determine NCI-led from recruitment trial, EMD initial stage will advanced successfully PDSXXXX completed. triple and eight has safety X benchmark patients edge the the Serono's the of associated this In combination cancers. The trial, efficacy furthers the is the results in a with Second, evaluating
this pre-clinical is from November to of Agency, vaccine. MUCX progression for via Regulatory and ANVISA COVID-XX we the platform highly oncology point. studies breast, Universal that cancer associated August, the the Cancer in this immunogenic of protein pipeline. we with Farmacore X several the Fifth, Biotech's oncology PDSXXXX about with IND novel highly our utility PDSXXXX our was peptides, in And start as and has and PDSXXXX, PDS which ovarian of pre-clinical of initiated. X, PDS cancers, lung developed. successful detail million Vaccine, Biotech offering, pipeline. like $XX collaboration prognosis the in in from provide types Brazil, PDS and drug advancements of immunotherapy on Flu in and years public Third, two Versamune to to to I which in and is will closed our cancer I shown the raise a being in requirements with more is provide which development finally, expect colorectal, the resistance National the would of disease agreed PDSXXXX by of and recent initiate combines capital trials Mucin expressed clinical bit be with working approximately approximately Biotech pipeline past Institute Fourth, product Friday, been Brazilian PDSXXXX or proprietary poor MUCX. known, for derived associated
As National Center. all there National Merck, trials Anderson the Cancer and including developed initiated. MD University are in with Phase renowned field, world or Institute X of partnerships PDSXXXX, Institute ongoing through Texas investigator of NCI, are the Anderson which of The Cancer the MD oncology leaders Cancer been today, three and have of trials
all XXX% compounds. PDS reminder, a based of Biotech other PDSXXXX Versamune As ownership and retains
strategy platforms that is deliver two X care the We higher VERSATILE three recurrent standard unique standard advantage of or combining of care of addressing demonstrated as PDSXXXX our Phase in combination It XXX, Versamune of X and to the in have of metastatic disease. is treatment options safety trial combination first outcomes and our line taken potency, of two noteworthy to the patients. trials one of to pursue ongoing quality Phase with of studies with therapeutic cancer
combination Phase clinical PDSXXXX trial, VERSATILE successfully Cancer demonstration X initiation we in effects trial, is VERSATILE anti-cancer the Institute form the across powerful combination November NCI’s improved this is led third in triple X, of cancers. platform on this unique could based providing triple studies. and preclinical on basis ongoing preclinical The cancer data publication multiple the independent Monday, confirmed National our If announced of of XXX trial. a combination the treatments XXX, The
metastatic evaluating The and is as anti-PD-X label, immune-based open of XXX combination multi-center, first VERSATILE non-randomized approximately study trial our adverse head with the inhibitor, of pembrolizumab for Keytruda reminder, has a cancer. also recurrent single-arm, of checkpoint PDSXXXX a treatment neck XXX As patients. line or known
Merck and PDS will providing fully partner of be Biotech responsible study. is day-to-day Our for drug the the management
combination. this with two the or delayed to of and will we spread avoid it has drugs, clinical provide careful to impact for of PDSXXXX metastatic trial. the take that be recurrent benefits We to means significantly chosen due was following to returned Merck, clinical and pandemic Keytruda patients, able treatment with collaboration of COVID-XX cancer has appealing compared the potential approach the alone. initiation initial and may systems operations. We patients XXX the chemotherapy proceed therapy improved compromised trial of determined an of We're with combination to hopeful This safe patients And improved efficacy for cancer that head maybe to by or believe and treatment, been more chemotherapy that clinical that line immunotherapy immune after have patients. sites, as that the neck to allow first the very functional not enrolling the whose tremendous Keytruda combination that extensive VERSATILE previously have on consideration in with
Now trials. moving initiated on to our investigator
tumors, ongoing entry patient an responses. of rectal, enhance an is HPV cell, novel cytokine PDSXXXX advanced to an esophageal associated prior first a checkpoint clinical XXX, vulvar, first-in-class Dr. X trial of to we in trial cancer. addition inhibitor safety to of in progress immunotherapies. this X led and with cancer, cytokines, In cancers. facilitate shortly. clinical including Any led National T-cell enroll of local treatment for the HPV The to who standard On conjugated anal, additional Anderson triple a of bi-functional study Wood MD or two failed investigate MXXXX, have locally XX, initiation chemoradiotherapy, Institute of being vaginal, initiated Cancer lung cervical, these of designed the also head squamous provide Phase and neck, types several CRT, This of have will outcomes with NHS-IL and in trial. novel penile is announced ILXX Phase combination. combination X ongoing our October and associated efficacy is stage cervical the of evaluating about treatment the to or eligible with XX, trials. will details advanced furthest other PDSXXXX preliminary patients we this This cancers VERSATILE care with trial, investigator trials combination into advanced Phase line PDSXXXX two studied antibody combination
with care to also commercial significantly Phase path proof market It standard have of mitigate believe care strategy strategy our approval, of our rapid risk benefit current X this development expansion. we clear over clinical of also Our concept PDSXXXX goal, standard compounding toxicity. initial in trials. for is we standard of enhanced If designed combining and potential towards demonstrate is the of of with without to will do of penetration for PDSXXXX After the treatment patients commercialization us to achieve positions that care, designed PDSXXXX. we combining a clinical
the of silent introduced HPV you described due rapidly for There of and is the cancers expected several been new incidences of large Anal remain some about may cancer has cancer. cancer alone. very first the been incidence preventive United as HPV increasing. despite XX,XXX robust currently next also to XXXX. HPV of in use decades, vaccines, the and a this to As neck increasing already incidence associated every are these know, has steadily the in market year cancer States head epidemic
to For million, both plus PDSXXXX. responsibility investigator supply obligation is initiated an financial trials combined, limited $X our to approximately
is and Cancer to highly of pipeline peptides our and biology Research the moving with and combines PDSXXXX. expansion we studies developed peptides known Versamune the Now to due CDX of include associated associated In drug ability PDSXXX demonstrated PDSXXXX PDSXXX, Laboratory to often immunogenic National similar to tumor In were killer resistance. novel disease derived and our MUCX tumor by prognosis expressed at poor the lung MUCX protein Agreements, These is MUCX cancers PDS Cooperative the colorectal, breast, PDSXXXX. four of of immunology and to to proprietary wide of Institute April, Biotech, National from Expression range as novel of ovarian announced Institute. MUCX. cancers. the in Development Cancer a T-cells. CRADA, including interest in studies, with proprietary cancer or specific with on types, the powerful and part preclinical generate
that is and a better will by MUCX MUCX to hope the in malignant allowing kill and system see results, similar immune proteins Our humans, tumors. cells recognize expressing expressed we the attack
is are work formulation to announce complete. PDSXXXX pleased We that
preclinical For anticipate the of will PDSXXXX completed half a final be in studies with ahead agents of preclinical studies the of during initiating study. We be preclinical National XXXX. immunotherapeutic planned of first stage Cancer development, that the the other will Institute combination clinical human
program advancing PDSXXXX our chosen to PDSXXXX flu NIAID Pre-clinical induction previous development develop is and as that to to PDS Brazil's on drug regulatory with November agency as novel study. a and preclinical Biotech’s Earlier vaccine our the November on the has has the in end, with To announced X the and COVID-XX Farmacore July preclinical of we this development Brazil. program extend the clinical XX, granted We emerging on to announced vaccine June that with our of and Phase program now been and infectious PDSXXXX will T-cell long-term of agreement update the trial Farmacore. an PDSXXXX Farmacore with in program to results. the and Vaccine. we initiated Based upcoming is are we government they by a streamline multiple vaccine clinical Turning from protecting agreed our Farmacore durability of submission partner human data well virus. of replace Farmacore, the trial of pipeline data X/X will human on is package the that an for become protocol. Versamune-Based goal population strains human promising in as as final Influenza specific the Universal been prepare we for and this Based week, Please against official Farmacore response develop results COVID-XX product provide we will effective have cover XX, forward in PDSXXXX immune partnership the both clinical the antibodies pipeline. promote its discussions to be agencies details disease of more that on to is T-cells award it in developing note preclinical a announced ANVISA situation FDA met COVID-XX clear counterpart review to ANVISA, from first Friday, and in path last anticipated to available. funding paramount. a Brazil, that several half as this XXXX. begin countries, collaborator responses
preclinical result, are studies we a term of As PDSXXXX. additional conducting longer
COVID-XX. the full are including of for a of completion. complete for into program initially The peer vaccine on these provide critical While are durability be against data of to antibody not and potential this review the help will long-term the responses attain this T-cell set studies important preclinical immune they a advancing to protection clinic, robust more understanding submitted
have globally the full presents breadth helper antibody not also and killer I T-cells. will rather commercialization, virus-specific I must go critical be immune vaccine of This responses, characteristics that As to vaccine responses induce including optimal the protection means to a program. in successful. CDX COVID-XX but CDX raise necessary develop long-term provide to the memory, and the past, to and T-cells said vaccine design that the with and It's
being should scalable, scale, production of simple, PDSXXXX commercial each also of be capable developed the commercial demonstrate these to qualities. For success, long-term safe, stability. exhibit vaccine is and at rapidly
development as informed progresses. you keep will We
financial a common our approximately completed September raised balance reminder, cash XXth just $XX offering, million under as a to we and August, position, which on Moving as our $XX in is million. stock of
been conserving with our pipeline, has and institutions capital to to strategy while class resources. our strengthen partner knowledge advance ongoing world Our scientific our
sufficient readouts his trials. announced to cash is data provide through our the details during King, of previously initiatives will PDSXXXX today's additional of a shortly. our As remarks prepared result, our CFO balance our initial clinical Michael support interim portion
Chief our review Lauren to the Medical Officer, Now call clinical I'd turn our to to like updates, Dr. over Wood.
